Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups

Diabetes, Obesity and Metabolism

Volumn 8, Issue 5, 2006, Pages 568-573

  Hompesch, M ^a   Troupin, B ^a   Heise, T ^b   Elbroend, B ^c   Endahl, L ^c   Haahr, H ^c   Heinemann, Lutz ^b  

^a Profil Institute for Clinical Research   (United States)

^b Profil Institut für Stoffwechselforschung   (Germany)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Basal insulin; Ethnicity; Glucodynamics; Pharmacokinetics; Variability

Indexed keywords

C PEPTIDE; GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN DETEMIR; ISOPHANE INSULIN; LONG ACTING INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AFRICAN AMERICAN; AGED; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC GROUP; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; HISPANIC; HUMAN; INSULIN BLOOD LEVEL; INSULIN INFUSION; MALE; MAXIMUM LIKELIHOOD METHOD; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 33746910579     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00643.x     Document Type: Article

References (15)

1. Diaz VA, Mainous AG, Koopman RJ, Geesey ME. Are ethnic differences in insulin sensitivity explained by variation in carbohydrate intake? Diabetologia 2005; 48: 1264-1268.
2. Markussen J, Havelund S, Kurtzhals P et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996; 39: 281-288.
3. Kurtzhals P, Havelund S, Jonassen I et al. Albumin binding of insulins acylated with fatty acids: Characterization of the ligand-protein interaction and correlation between affinity and timing of the insulin effect in vivo. Biochem J 1995; 321: 725-731.
4. Heise T, Nosek L, Stender A et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620.
5. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time-action profile of the soluble, fatty acid acylated long-acting insulin analogue NN304. Diabet Med 1999; 16: 332-338.
6. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28: 1107-1112.
7. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: A randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001; 24: 296-301.
8. Vague P, Selam J - L, Skeie S et al. Insulin detemir is associated with more predictable glycaemic control and lower risk of hypoglycaemia compared to NPH insulin in subjects with type 1 diabetes. Diabetes Care 2003; 26: 590-596.
9. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of once-daily insulin detemir or NPH insulin on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26: 724-736.
10. Pieber T, Draeger E, Kristensen A, Grill V. Comparison of three multiple regimens for type 1 diabetes: Morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005; 22: 850-860.
11. Home P, Bartley P, Russell-Jones D et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomised clinical trial. Diabetes Care 2004; 27: 1081-1087.
12. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56-64.
13. Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 2004; 6: 579-588.
14. Jhee SS, Lyness WH, Rojas PB, Leibowitz MT, Zarotsky V, Jacobsen LV. Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy Caucasian and Japanese American subjects. J Clin Pharmacol 2004; 44: 258-264.
15. Hermansen K, Derezinski T, Kim H, Gall M - A. Treatment with insulin detemir in combination with oral agents is associated with less risk of hypoglycaemia and less weight gain than NPH insulin at comparable levels of glycaemic improvement in people with type 2 diabetes (abstract). Diabetologia 2004; 47 (Suppl. 1): A273.